BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 17714826)

  • 1. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
    Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
    Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
    Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
    Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
    Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
    Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
    Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
    Takenaka K; Ishikawa S; Yanagihara K; Miyahara R; Hasegawa S; Otake Y; Morioka Y; Takahashi C; Noda M; Ito H; Wada H; Tanaka F
    Ann Surg Oncol; 2005 Oct; 12(10):817-24. PubMed ID: 16132376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.
    Pesta M; Kulda V; Topolcan O; Safranek J; Vrzalova J; Cerny R; Holubec L
    Anticancer Res; 2009 Nov; 29(11):4535-9. PubMed ID: 20032402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
    Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer.
    Cho YB; Lee WY; Song SY; Shin HJ; Yun SH; Chun HK
    Hum Pathol; 2007 Nov; 38(11):1603-10. PubMed ID: 17669467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
    Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
    J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.
    van der Jagt MF; Sweep FC; Waas ET; Hendriks T; Ruers TJ; Merry AH; Wobbes T; Span PN
    Cancer Lett; 2006 Jun; 237(2):289-97. PubMed ID: 16046057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
    Song SY; Son HJ; Nam E; Rhee JC; Park C
    Eur J Cancer; 2006 Jan; 42(1):101-8. PubMed ID: 16324834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with Kazal motifs in murine cell lines.
    Takagi S; Hoshino Y; Osaki T; Okumura M; Fuginaga T
    Exp Oncol; 2007 Mar; 29(1):30-4. PubMed ID: 17431385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
    Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
    Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness.
    Kang HG; Kim HS; Kim KJ; Oh JH; Lee MR; Seol SM; Han I
    J Orthop Res; 2007 May; 25(5):696-702. PubMed ID: 17262820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.
    van Lent PL; Span PN; Sloetjes AW; Radstake TR; van Lieshout AW; Heuvel JJ; Sweep CG; van den Berg WB
    Ann Rheum Dis; 2005 Mar; 64(3):368-74. PubMed ID: 15485996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer.
    Chang HC; Cho CY; Hung WC
    Cancer Sci; 2007 Feb; 98(2):169-73. PubMed ID: 17233834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
    Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
    Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
    Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
    Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
    Cox G; Jones JL; O'Byrne KJ
    Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.